Skip to main content

Table 2 Secondary Outcomes According to Treatment Group

From: Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts

 

Indomethacin

Ibuprofen

 
 

(N = 161)

(N = 182)

p value

Day of Life at Start of Treatment (mean, SD)

3.3 ± 2.3

3.5 ± 2.7

NS

PDA Closed, n (%)

109 (68)

129 (71)

0.4

PDA Ligation, n (%)

45 (28)

38 (21)

0.1

BPD, n (%)

72 (45)

90 (49)

0.2

NEC-related conditions, any, n (%)

27 (17)

32 (18)

0.8

NEC, n (%)

6 (4)

15 (8)

0.08

   NEC-Like Illness (%)

13 (8)

5 (3)

0.03*

   Spontaneous Intestinal Perforations, n (%)

8 (5)

12 (7)

0.5

ROP, n (%)

65 (52)

41 (30)

<0.001*

Severe ROP: Grades III-V

15 (12)

15 (11)

0.8

IVH, any, n (%)

58 (36)

57 (31)

0.4

Severe IVH: Grade III/IV

12 (8)

12 (9)

0.6

PVL

4 (2.4)

3 (1.6)

0.4

Death, n (%)

12 (7)

16 (9)

0.4

  1. PDA, patent ductus arteriosus; BPD, bronchopulmonary dysplasia; NEC, necrotizing enterocolitis; ROP, retinopathy of prematurity; IVH, intraventricular hemorrhage; PVL, periventricular leukomalacia.
  2. The denominator for the percent (%) for each secondary outcome reflects the number of patients with evaluation of that outcome - for ROP in particular, 82 infants did not have a retinal exam.
  3. * denotes statistically significant difference between treatments, p < 0.05